Real-life Performance Evaluation of the LiFlow X-ray Platform

NCT06999538 | Not Yet Recruiting

• 1 other identifier: 49RC25_0203
• Study Type: observational
• Target: 400
• Locations: 0 countries
• Sites: N/A

Brief Summary

The thoraco-abdomino-pelvic (TAP) scanner is crucial for assessing and monitoring solid cancers. However, advancements in scanner technology have led to a significant increase in data volume, from 100 images per exam 20 years ago to 2,000 today. The rising number of cancer cases and treatments requiring closer monitoring further strain the workload, prolonging interpretation time and causing delays in therapeutic management and adjustments. The limited number of radiologists contributes to this saturation, increasing the risk of missing metastatic lesions, especially in the lungs, liver, bones, peritoneum, and lymph nodes. The RECIST 1.1 criteria, introduced 15 years ago for standardized follow-up, are useful but time-consuming to implement, resulting in only a small fraction of oncology CT reports using them.

Conditions

Solid Cancers

Outcome Measures

Primary Outcomes (1)

• Time elapsed between opening and closing, oncology interpretation completed, of the same file interpreted

  1 day

Secondary Outcomes (7)

• Number of additional relevant lesions discovered

  Day 1

• Duration recorded for examinations with no relevant lesions and pathological examinations

  Day 1

• Recorded times for initial and follow-up examinations

  Day 1

• Location and size of lesion(s) on report and nature of primary tumor in patient file

  Day 1

• Number of lesions detected

  Day 1

Interventions

Radiologist interpretation OTHER

two interpretations (with and without Liflow, oncology imaging tool).

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

patients treated for solid cancer

You may qualify if:

• TAP (thoraco-abdomino-pelvic) scans
• Age \> 18 years

You may not qualify if:

• Examination of imperfect quality due to movement or breathing,
• Inability to inject contrast medium or incomplete injection
• refusal to use data

Sponsors & Collaborators

• University Hospital, Angers: lead

Study Officials

• Christophe Aube

  University Hospital, Angers

  STUDY CHAIR

Central Study Contacts

Christophe Aube

CONTACT

241353637; christophe.aube@chu-angers.fr

DRCI Promotion interne

CONTACT

drci-promotion-interne@chu-angers.fr

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER GOV
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 22, 2025
• First Posted: May 31, 2025
• Study Start: September 1, 2025
• Primary Completion (Estimated): September 1, 2026
• Study Completion (Estimated): September 1, 2026
• Last Updated: May 31, 2025

Record last verified: 2025-05